Table 2.

Patient demographics and baseline Charlson comorbidity index

	Patients newly diagnosed with ATTRv amyloidosis N = 185
Age, years, mean (SD)	59.2 (15.2)
18–34, n (%)	14 (7.6)
35–54	46 (24.9)
55–64	62 (33.5)
65+	63 (34.1)
Gender, n (%)
Female	100 (54.1)
Male	85 (45.9)
Region, n (%)
Midwest	38 (20.5)
Northeast	68 (36.8)
South	64 (34.6)
West	15 (8.1)
Insurance type, n (%)
PPO/POS	122 (65.9)
Comprehensive	23 (12.4)
CDHP/HDHP	21 (11.4)
HMO	17 (9.2)
Missing/unknown	2 (1.1)
Charlson comorbidity index, mean (SD)	2.2 (2.5)

ATTRv hereditary transthyretin, CDHP/HDHP consumer directed health plan/high deductible health plan, HMO health maintenance organization, PPO/POS preferred provider organization/point of service plan